---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-138563"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:44:10.353477+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology prioritizes PYX-201 after 50% ORR in HNSCC; suspends PYX-106

## Summary
- Confirmed 50% ORR and 100% DCR in 6 heavily pretreated HNSCC patients in Phase 1 of PYX-201.
- Across 6 solid tumor types (n=31), PYX-201 achieved 26% ORR with dose-dependent responses in taxane-pretreated patients.
- PYX-106 program suspended; Phase 1 monotherapy enrolled 45 patients, was safe and well-tolerated.
- Current cash position expected to fund PYX-201 monotherapy and combination trials into 2H 2026.
- Monotherapy and pembrolizumab combination trials for PYX-201 expected to start dosing in early 2025.

## SEC filing metadata
- accession: 0000950170-24-138563
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017024138563/0000950170-24-138563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017024138563/pyxs-20241219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-138563
- JSON: https://secwatch.observer/filing/0000950170-24-138563.json
- Plain text: https://secwatch.observer/filing/0000950170-24-138563.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.